.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,722,917

« Back to Dashboard

Details for Patent: 8,722,917

Title:Boron-containing small molecules
Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
Inventor(s): Baker; Stephen J. (Mountain View, CA), Akama; Tsutomu (Sunnyvale, CA), Alley; Michael Richard Kevin (Santa Clara, CA), Benkovic; Stephen J. (College, PA), Dipierro; Michael (Wadsworth, IL), Hernandez; Vincent S. (Watsonville, CA), Hold; Karin M. (Belmont, CA), Kennedy; Isaac (Bollingbrook, IL), Likhotvorik; Igor (Morton Grove, IL), Mao; Weimin (Sunnyvale, CA), Maples; Kirk (San Jose, CA), Plattner; Jacob J. (Orinda, CA), Rock; Fernando (Los Altos, CA), Sanders; Virginia (San Francisco, CA), Stemphoski; Aaron M. (Florence, SC), Yiannikouros; George Petros (Florence, SC), Zagar; Siead (Orlando Park, IL), Zhang; Yong-Kang (San Jose, CA), Zhou; Huchen (Shanghai, CN)
Assignee: Anacor Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:Jan 23, 2012
Application Number:13/356,488
Claims:1. A compound, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula: ##STR00248## in which R.sup.1 and R.sup.2 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; wherein R.sup.1 and R.sup.2, together with the atoms to which they are attached, can be optionally joined to form a 4- to 7-membered ring; Z1 is a member selected from ##STR00249## wherein R.sup.3a and R.sup.4a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; R.sup.5 is a member selected from halogen and OR.sup.8 wherein R.sup.8 is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, unsubstituted aryl, and substituted or unsubstituted heteroaryl R.sup.9a is H, R.sup.11a is H, R.sup.12a is H, and R.sup.10a is halogen.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and R.sup.2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl and wherein R.sup.1 and R.sup.2, together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane and substituted or unsubstituted dioxaborepane.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and R.sup.2, together with the atoms to which they are joined, form a member selected from dioxaborolane, substituted or unsubstituted tetramethyldioxaborolane, substituted or unsubstituted phenyldioxaborolane, dioxaborinane, dimethyldioxaborinane and dioxaborepane.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Z1 is ##STR00250## and R.sup.5 is substituted or unsubstituted tetrahydro-2H-pyran-2-yloxy.

5. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.3a is H and R.sup.4a is a member selected from methyl, ethyl, propyl, butyl, phenyl, benzyl and cyano.

6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R.sup.10a is a member selected from the group consisting of fluoro, chloro, and bromo.

7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula: ##STR00251##

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from ##STR00252## ##STR00253##

9. A compound, or a pharmaceutically acceptable salt thereof, having a structure according to the formula: ##STR00254## in which X is a member selected from substituted or unsubstituted triflate, halogen, substituted or unsubstituted sulfonic esters and substituted or unsubstituted acyloxy groups, and substituted or unsubstituted diazo; R.sup.1 and R.sup.2 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. R.sup.1 and R.sup.2, together with the atoms to which they are attached, can be optionally joined to form a 4- to 7-membered ring; R.sup.3a and R.sup.4a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; R.sup.9a, R.sup.10a, R.sup.11a and R.sup.12a are members independently selected from H, OR*, NR*R**, SR*, --S(O)R*, --S(O).sub.2R*, --S(O).sub.2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; wherein each R* and R* * are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl with the proviso that that the compound is not: ##STR00255##

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and R.sup.2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstitutcd isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl and wherein R.sup.1 and R.sup.2, together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane and substituted or unsubstituted dioxaborepane.

11. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and R.sup.2, together with the atoms to which they are joined, form a member selected from dioxaborolane, substituted or unsubstituted tetramethyldioxaborolane, substituted or unsubstituted phenyldioxaborolane, dioxaborinane, dimethyldioxaborinane and dioxaborepane.

12. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said X is a member selected from triflate, chloro, bromo, iodo, substituted or unsubstituted sulfonic esters, substituted or unsubstituted acyloxy groups, and substituted or unsubstituted diazo.

13. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said R.sup.3a is H and R.sup.4a is a member selected from methyl, ethyl, propyl, butyl, phenyl, benzyl and cyano.

14. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R.sup.9a is H, R.sup.11a is H, R.sup.12a is H, R.sup.10a is a member selected from the group consisting of halogen, cyano, nitro, substituted or unsubstituted methoxy, substituted or unsubstituted methyl, substituted or unsubstituted ethoxy, substituted or unsubstituted ethyl, trifluoromethyl, substituted or unsubstituted hydroxymethyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted benzyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenyloxy, substituted or unsubstituted phenyl methoxy, substituted or unsubstituted thiophenyloxy, substituted or unsubstituted pyridinyloxy, substituted or unsubstituted pyrimidinyloxy, substituted or unsubstituted benzylfuran, substituted or unsubstituted methylthio, substituted or unsubstituted mercaptomethyl, substituted or unsubstituted mercaptoalkyl, substituted or unsubstituted phenylthio, substituted or unsubstituted thiophenylthio, substituted or unsubstituted phenyl methylthio, substituted or unsubstituted pyridinylthio, substituted or unsubstituted pyrimidinylthio, substituted or unsubstituted benzylthiofuranyl, substituted or unsubstituted phenylsulfonyl, substituted or unsubstituted benzylsulfonyl, substituted or unsubstituted phenylmethylsulfonyl, substituted or unsubstituted thiophenylsulfonyl, substituted or unsubstituted pyridinylsulfonyl, substituted or unsubstituted pyrimidinylsulfonyl, substituted or unsubstituted sulfonamidyl, substituted or unsubstituted phenylsulfinyl, substituted or unsubstituted benzylsulfinyl, substituted or unsubstituted phenylmethylsulfinyl, substituted or unsubstituted thiophenylsulfinyl, substituted or unsubstituted pyridinylsulfinyl, substituted or unsubstituted pyrimidinylsulfinyl, substituted or unsubstituted amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted trifluoromethylamino, substituted or unsubstituted aminomethyl, substituted or unsubstituted alkylaminomethyl, substituted or unsubstituted dialkylaminomethyl, substituted or unsubstituted arylaminomethyl, substituted or unsubstituted benzylamino, substituted or unsubstituted phenylamino, substituted or unsubstituted thiophenylamino, substituted or unsubstituted pyridinylamino, substituted or unsubstituted pyrimidinylamino, substituted or unsubstituted indolyl, substituted or unsubstituted morpholino, substituted or unsubstituted alkylamido, substituted or unsubstituted arylamido, substituted or unsubstituted ureido, substituted or unsubstituted carbamoyl, and substituted or unsubstituted piperizinyl.

15. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein R.sup.10a is a member selected from the group consisting of fluoro, chloro, bromo, nitro, cyano, amino, methyl, hydroxylmethyl, trifluoromethyl, methoxy, trifluoromethyoxy, ethyl, diethylcarbamoyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidinyl, piperizino, piperizinyl, piperizinocarbonyl, piperizinylcarbonyl, carboxyl, 1-tetrazolyl, 1-ethoxycarbonylmethoxy, carboxymethoxy, thiophenyl, 3-(butylcarbonyl)phenylmethoxy, 1H-tetrazol-5-yl, 1-ethoxycarbonylmethyloxy-, 1-ethoxycarbonylmethyl-, 1-ethoxycarbonyl-, carboxymethoxy-, thiophen-2-yl, thiophen-2-ylthio-, thiophen-3-yl, thiophen-3-ylthio, 4-fluorophenylthio, butylcarbonylphenylmethoxy, butylcarbonylphenylmethyl, butylcarbonylmethyl, 1-(piperidin-1-yl)carbonyl)methyl, 1-(piperidin-1-yl)carbonyl)methoxy, 1-(piperidin-2-yl)carbonyl)methoxy, 1-(piperidin-3-yl)carbonyl)methoxy, 1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl)methoxy, 1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl)methyl, 1-(4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl, 1-4-(pyrimidin-2-yl)piperazin-1-yl, 1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl), 1-(4-(pyridin-2-yl)piperazin-1-yl)carbonylmethyl, (1-(4-(pyridin-2-yl)piperazin-1-yl)carbonyl)-methoxy), 1-(4-(pyridin-2-yl)piperazin-1-yl, 1H-indol-1-yl, morpholino-, morpholinyl, morpholinocarbonyl, morpholinylcarbonyl, phenylureido, phenylcarbamoyl, acetamido, 3-(phenylthio)-1H-indol-1-yl, 3-(2-cyanoethylthio)-1H-indol-1-yl, benzylamino, 5-methoxy-3-(phenylthio)-1H-indol-1-yl, 5-methoxy-3-(2-cyanoethylthio)-1H-indol-1-yl)), 5-chloro-1H-indol-1-yl, 5-chloro-3-(2-cyanoethylthio)-1H-indol-1-yl)), dibenzylamino, benzylamino, 5-chloro-3-(phenylthio)-1H-indol-1-yl)), 4-(1H-tetrazol-5-yl)phenoxy, 4-(1H-tetrazol-5-yl)phenyl, 4-(1H-tetrazol-5-yl)phenylthio, 2-cyanophenoxy, 3-cyanophenoxy, 4-cyanophenoxy, 2-cyanophenylthio, 3-cyanophenylthio, 4-cyanophenylthio, 2-chlorophenoxy, 3-chlorophenoxy, 4-chlorophenoxy, 2-fluorophenoxy, 3-fluorophenoxy, 4-fluorophenoxy, 2-cyanobenzyloxy, 3-cyanobenzyloxy, 4-cyanobenzyloxy, 2-chlorobenzyloxy, 3-chlorobenzyloxy, 4-chlorobenzyloxy, 2-fluorobenzyloxy, 3-fluorobenzyloxy, and 4-fluorobenzyloxy.

16. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from ##STR00256##

17. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from: ##STR00257## ##STR00258## ##STR00259## ##STR00260## ##STR00261##

18. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from: ##STR00262## ##STR00263## ##STR00264## ##STR00265## ##STR00266## ##STR00267##

19. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and said R.sup.2 are each members independently selected from H, substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, substituted or unsubstituted isopropyl, substituted or unsubstituted butyl, substituted or unsubstituted t-butyl, substituted or unsubstituted phenyl and substituted or unsubstituted benzyl.

20. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and said R.sup.2 are each members independently selected from R.sup.1 and R.sup.2, together with the atoms to which they are joined, can optionally form a member selected from substituted or unsubstituted dioxaborolane, substituted or unsubstituted dioxaborinane, substituted or unsubstituted dioxaborepane.

21. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said X is a sulfonic ester group which is selected from the group consisting of substituted or unsubstituted mesylate, substituted or unsubstituted tosylate, substituted or unsubstituted brosylate and substituted or unsubstituted nosylate.

22. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said X is an acyloxy group which is substituted or unsubstituted acetoxy or substituted or unsubstituted trifluoroacetoxy.

23. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said X is selected from the group consisting of bromo, iodo, mesylate and diazo.

24. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said X is bromo or iodo.

25. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein said compound is ##STR00268##

26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and R.sup.2 are each members independently selected from H, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, phenyl and benzyl.

27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and said R.sup.2 are each members independently selected from H, methyl, isopropyl, and phenyl.

28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and said R.sup.2 are methyl.

29. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and said R.sup.2 are isopropyl.

30. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said R.sup.1 and said R.sup.2 are H.

31. The compound of claim 1, or a pharmaceutically acceptable salt thereof, having a structure according to the following formula: ##STR00269##

32. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is a member selected from ##STR00270##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc